Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.67 |
| ▸ | DRD3 | P35462 | 3/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043245 | 0.87 | SIGMAR1 (0.71) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL4040849 | 0.83 | ABCB1 (0.79) | ABCB1ABCG2 | |
| SCHEMBL9433141 | 0.83 | ABCB1 (0.69) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL7170168 | 0.82 | SIGMAR1 (0.56) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL4042171 | 0.81 | SIGMAR1 (0.71) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL8285666 | 0.81 | SIGMAR1 (1.00) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL8285657 | 0.79 | SIGMAR1 (1.00) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL13631985 | 0.79 | SIGMAR1 (0.81) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL1887340 | 0.78 | SIGMAR1 (0.86) | SIGMAR1DRD3DRD2DRD4TMEM97 | |
| SCHEMBL12673255 | 0.77 | SIGMAR1 (0.85) | SIGMAR1DRD3DRD2DRD4TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934276-B1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LTD (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-6218393-B1 | IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG | XENOVA LIMITED (GB) | 2001-04-17 | — | — | US | disclosed |